Israel's temporary restriction on glyoxylic acid in hair-straightening cosmetics runs through 31 December 2027. The pharmacists order, signed on 3 February 2026, inserts the substance for that use into the prohibited-ingredient framework applied under Israeli cosmetics law. Its scope is defined by the ingredient and intended use, rather than the supplier's country.1
The order is relevant to the wider opening of cosmetics imports because Israel has retained a specific safety exception. Israel Hayom's report on the parliamentary committee's approval explains that earlier import liberalisation created a need to restate the restriction explicitly. It describes the measure as following a Health Ministry review of clinical reports, laboratory evidence and specialist advice.2
Hairdressers supported the restriction
Israel's Craft and Industry Association said the Health Ministry published the measure on 10 February 2026. Its hairdressers' branch welcomed the decision and called for better training and supervision in salons. Branch chairman Michel Mercier also urged officials to:3
להאריך את תקופת האיסור
extend the prohibition period.3
That is the association's requested policy, distinct from the expiry date in the order. The group also announced plans to send products for outside laboratory tests. Its statement establishes the intended checks, not evidence that every product on the market had subsequently been tested or found compliant.3
The Israeli reporting records why the ministry sought a product-specific intervention: the evidence concerned serious kidney injury following straightening treatments. Officials considered the broader import reform alongside the power to exclude an ingredient where they judged the safety risk unacceptable. A simpler route for compliant cosmetics consequently does not remove ingredient restrictions.2
France raised concerns and Europe commissioned further assessment
France's health and environmental safety agency ANSES published its assessment on 23 January 2025. It said the available evidence made glyoxylic acid a highly probable cause of acute kidney injury and recommended a European risk assessment to determine whether restrictions or a prohibition were warranted. It also urged businesses placing relevant products on the market to reassess their safety.4
ANSES distinguished its scientific assessment from a product-by-product list. The work concerned the substance's toxicity and did not identify every brand that should be avoided. For the trade, that means checking the formulation and intended use remains material; a distributor cannot infer compliance solely from a familiar brand or the fact that a product was offered abroad.4
The European Commission published a request for an opinion from its Scientific Committee on Consumer Safety on 4 May 2026. The mandate asks whether the ingredient is safe in straightening products at concentrations up to 16%, what lower concentration might be safe, and whether other cosmetic uses raise concerns. It allows twelve months for the work. Those questions are a research mandate, not an authorised safe concentration or an enacted European ban.5
The open regulatory question is what that European assessment concludes and whether Israel changes the temporary restriction before its stated expiry.1 5